NCT02772159 - TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

TD-4208

One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.

Trial Locations (1)

68502

Celerion, Lincoln